Some Ozepic users are developing serious eye issues

Blockbuster GLP-1 drugs such as ozepic and Mounjaro can sharpen your figure, but they can also catch your vision in the process.

A compilation published in Jama Ophthalmology discovered at least nine cases of patients who suffered vision loss after receiving semaglutide or tirzepatide, active ingredients in Wegovy and Zepbound, respectively.

This study adds an increasing research organ that documents vision problems in patients using these medicines. A 2024 study suggested a possible link between semaglutid and the rare condition of the eye of the neuropathy ischemic lateral ischemic (Naion), in which the restriction of blood flow to the optical nerve causes sudden vision.

The revision, led by doctors-scientists from the center of John A. Moran University of Utah, found that patients receiving GLP-1 developed three potentially dazzling conditions affecting the optical nerve-part of your eye sending visual information to the brain.

Seven patients suffered Naion -like symptoms; One had papill, an inflammation of the optic nerve head; And a developed acute acute acute maculopathy, which can cause a blind spot in vision.

The authors note that patients, all in the 1950s and 60s, were prescribed semaglutide or tirzepatide due to diabetes or overweight, along with other cardiovascular conditions, all of which can contribute to the problems of their own vision.

“We are trying to clarify if being in these medicines can increase your risk,” said Norah S. Lincoff, co -author of the newspaper and professor of neurology at the University in Buffalo.

Researchers hypothesize that rapid changes in blood sugar caused by medicines can be responsible for these vision problems rather than a direct toxic effect on medication. But they stressed that they are still working to connect the points.

“This summary was not made in any way we can say that these medicines caused complications,” said lead author Bradley Katz, an ophthalmologist and professor at Utah University. “Further studies are needed to try our hypothesis.”

Novo Nordisk, manufacturer of Ozepic and Wegovy, did not respond immediately to the request of the post for comment. Not even Eli Lilly, Maunjaro and Zepbound manufacturer.

While reports on vision problems in patients receiving semaglutid and tirzepatide are rare, researchers cite their flowering popularity as the cause of concern.

Originally developed to treat diabetes, demand for these medicines has increased as they were found to effectively promote weight loss. They work by imitating a hormone that the body produces after eating, helping users feel longer.

A 2024 study found that 12% of the US population received a GLP-1 drug at one point, with about 6% currently using them.

Common side effects include gastrointestinal issues such as nausea, vomiting and diarrhea. Users have also reported to experience erectile dysfunction, personality changes, increased reckless behavior and “Ozepic butt” and “infamous” breasts and “breasts” (hanging in all wrong places).

Doctors have also seen other unusual complications, such as allodynia, a kind of nerve pain where things that should not harm – how to wash your hair or wear a shirt – suddenly do.

However, the GLP-1 tendency shows no signs of slowdown, especially as new uses for medicines continue to appear. Wegovy’s label was updated last year to reflect its ability to reduce the risk of cardiovascular events such as heart attacks and strokes, while Zepbound’s label now involves treatment for moderate to severe obstructive sleep in adults .

Scientists are currently investigating the potential benefits of GLP-1 drugs for a wide range of conditions, including chronic kidney disease, fatty liver disease, dementia and Alzheimer. There is also a buzz about the use of these media to treat dependence and use disorders, following reports of reduced desires between users.

The study’s authors noted that the research is still ongoing to determine whether these drugs increase the risk of vision problems.

“The message to the primary care provider is, if a patient in one of these medicines calls you and says there is loss or loss of vision, let them see their ophthalmologist as soon as possible. Do not expect,” he said Lincoff.